GlassScriptPhysician profile
Ravi Pandey
NPI 1881675452
$12,451.15
in general payments reported to CMS, 2019-2025
35 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2020: $444 · 2021: $2,045 · 2022: $2,263 · 2023: $2,727 · 2024: $2,557 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,974.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,778.39 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,369.15 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $1,019.08 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $785.09 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $764.21 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $745.67 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $552.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $519.98 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $493.66 | 2020-2025 | |
| Abbvie INC. | $389.87 | 2021-2025 | |
| Abbott Laboratories | $361.60 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $251.33 | 2023-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $233.78 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Edwards Lifesciences Corporation | $225.90 | 2024-2025 | |
| Progenics Pharmaceuticals, INC. | $127.48 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $109.40 | 2024 | Repatha |
| Biohaven Pharmaceuticals, INC. | $101.47 | 2021 | |
| Paratek Pharmaceuticals, INC. | $99.71 | 2021-2025 | Nuzyra |
| Exact Sciences Corporation | $79.50 | 2023-2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $46.56 | 2025 | Austedo Xr |
| Reprise Biomedical, INC. | $40.66 | 2024 | Miro3d |
| Intuitive Surgical, INC. | $40.49 | 2021 | |
| Organogenesis INC. | $39.69 | 2021 | |
| Merck Sharp & Dohme LLC | $35.43 | 2021 | |
| Eisai INC. | $31.10 | 2021 | |
| Analog Devices INC. | $25.88 | 2024 | Sensinel Cpm Wearable |
| Avanir Pharmaceuticals, INC. | $23.63 | 2021 | |
| Allergan, INC. | $23.39 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.12 | 2025 | |
| Smith+Nephew, INC. | $22.25 | 2021 | |
| Almatica Pharma LLC | $19.88 | 2021 | |
| Nestle Healthcare Nutrition INC. | $19.87 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $19.38 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.10 | 2022 | |
| Grifols USA, LLC | $14.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Pandey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.